Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia SOF-SKN™ to progress to extension study in CLE patients Highlights • Lead clinical asset for the treatment of autoimmune skin diseases to progress to extension clinical study in patients...
SOF-SKN to progress to extension study in CLE patients
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Investor Presentation September 2026
- Novel oligonucleotides data presented at Options Conference
- Appendix 4E - Preliminary Financial Report
- New preclinical data supports immuno-oncology approach
- New study further validates Noxopharms cancer pipeline
Later from Noxopharm
- Audited Financial Statements
- FDA feedback supports SOF-SKN Phase II plans
- Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
- 2026 AGM Letter of Access, Notice of Meeting and Proxy
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm